Equities analysts expect Qiagen NV (NYSE:QGEN) to announce earnings of $0.36 per share for the current quarter, Zacks reports. Four analysts have provided estimates for Qiagen’s earnings. The highest EPS estimate is $0.37 and the lowest is $0.35. Qiagen posted earnings of $0.35 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 2.9%. The business is scheduled to announce its next quarterly earnings report on Monday, November 4th.
On average, analysts expect that Qiagen will report full-year earnings of $1.40 per share for the current fiscal year, with EPS estimates ranging from $1.34 to $1.43. For the next fiscal year, analysts forecast that the business will report earnings of $1.57 per share, with EPS estimates ranging from $1.51 to $1.62. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that cover Qiagen.
Qiagen (NYSE:QGEN) last released its quarterly earnings results on Wednesday, July 24th. The company reported $0.33 earnings per share for the quarter, missing analysts’ consensus estimates of $0.34 by ($0.01). Qiagen had a net margin of 12.94% and a return on equity of 12.10%. The business had revenue of $381.60 million during the quarter, compared to analyst estimates of $386.37 million. During the same quarter in the previous year, the firm posted $0.33 earnings per share. The firm’s quarterly revenue was up 1.2% on a year-over-year basis.
QGEN has been the topic of a number of recent analyst reports. Wolfe Research initiated coverage on shares of Qiagen in a report on Thursday, May 30th. They issued a “peer perform” rating on the stock. Barclays increased their target price on shares of Qiagen from $43.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday, June 21st. BNP Paribas raised shares of Qiagen from a “neutral” rating to an “outperform” rating in a research note on Friday, July 12th. Deutsche Bank reissued a “buy” rating on shares of Qiagen in a research note on Friday, July 26th. Finally, Goldman Sachs Group reissued a “buy” rating on shares of Qiagen in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company’s stock. Qiagen presently has a consensus rating of “Buy” and an average price target of $41.67.
Qiagen stock remained flat at $$36.34 during trading hours on Friday. 470,472 shares of the company’s stock were exchanged, compared to its average volume of 1,177,853. The firm has a market cap of $8.12 billion, a PE ratio of 27.12, a PEG ratio of 2.27 and a beta of 0.83. Qiagen has a 1-year low of $32.33 and a 1-year high of $41.55. The company has a current ratio of 1.77, a quick ratio of 1.59 and a debt-to-equity ratio of 0.54. The business’s 50 day moving average price is $39.50.
A number of institutional investors and hedge funds have recently modified their holdings of QGEN. O Shaughnessy Asset Management LLC purchased a new stake in shares of Qiagen during the first quarter worth approximately $30,000. Cornerstone Advisors Inc. bought a new stake in Qiagen during the 1st quarter worth approximately $44,000. Bessemer Group Inc. grew its position in Qiagen by 5,918.5% during the 2nd quarter. Bessemer Group Inc. now owns 1,625 shares of the company’s stock worth $66,000 after acquiring an additional 1,598 shares during the last quarter. Truvestments Capital LLC bought a new stake in Qiagen during the 1st quarter worth approximately $67,000. Finally, Rockefeller Capital Management L.P. grew its position in Qiagen by 83.1% during the 1st quarter. Rockefeller Capital Management L.P. now owns 2,113 shares of the company’s stock worth $86,000 after acquiring an additional 959 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.
Qiagen Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
See Also: Why do earnings reports matter?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.